Leila Tamara Alexander

Leila Tamara Alexander

Auto-generated profile, based on publicly available information

Leila Tamara Alexander

Biozentrum, University of Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2023 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
LALeila T. Alexander
Leila T. Alexander
JDJanani Durairaj
Janani Durairaj
AKAndriy Kryshtafovych
Andriy Kryshtafovych
Luciano AbriataLuciano Abriata
Luciano Abriata
YBYusupha Bayo
Yusupha Bayo
TSTorsten Schwede
Torsten Schwede
We present an in‐depth analysis of selected CASP15 targets, focusing on their biological and functional significance. The authors of the structures identify and discuss key protein features and evaluate how effectively these aspects were captured in the submitted predictions. While the overall ability to predict three‐dimensional protein structures continues to impress, reproducing uncommon features not previously observed in experimental structures is still a challenge. Furthermore, instances with conformational flexibility and large multimeric complexes highlight the need for novel scoring strategies to better emphasize biologically relevant structural regions. Looking ahead, closer integration of computational and experimental techniques will play a key role in determining the next challenges to be unraveled in the field of structural molecular biology.

25 September 2021 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
PDF file
LALeila T. Alexander
Leila T. Alexander
RLRosalba Lepore
Rosalba Lepore
AKAndriy Kryshtafovych
Andriy Kryshtafovych
AAAthanassios Adamopoulos
Athanassios Adamopoulos
MAMarkus Alahuhta
Markus Alahuhta
TSTorsten Schwede
Torsten Schwede
The biological and functional significance of selected Critical Assessment of Techniques for Protein Structure Prediction 14 (CASP14) targets are described by the authors of the structures. The authors highlight the most relevant features of the target proteins and discuss how well these features were reproduced in the respective submitted predictions. The overall ability to predict three‐dimensional structures of proteins has improved remarkably in CASP14, and many difficult targets were modeled with impressive accuracy. For the first time in the history of CASP, the experimentalists not only highlighted that computational models can accurately reproduce the most critical structural features observed in their targets, but also envisaged that models could serve as a guidance for further studies of biologically‐relevant properties of proteins.

19 May 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Alfredo MariAlfredo Mari
Alfredo Mari
TRTim Roloff
Tim Roloff
MSMadlen Stange
Madlen Stange
KSKirstine K. Søgaard
Kirstine K. Søgaard
EAErblin Asllanaj
Erblin Asllanaj
AEAdrian Egli
Adrian Egli
A variety of antiviral treatments for COVID-19 have been investigated, involving many repurposed drugs. Currently, the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp, encoded by nsp12-nsp7-nsp8) has been targeted by numerous inhibitors, e.g., remdesivir, the only provisionally approved treatment to-date, although the clinical impact of these interventions remains inconclusive. However, the potential emergence of antiviral resistance poses a threat to the efficacy of any successful therapies on a wide scale. Here, we propose a framework to monitor the emergence of antiviral resistance, and as a proof of concept, we address the interaction between RdRp and remdesivir. We show that SARS-CoV-2 RdRp is under purifying selection, that potential escape mutations are rare in circulating lineages, and that those mutations, where present, do not destabilise RdRp. In more than 56,000 viral genomes from 105 countries from the first pandemic wave, we found negative selective pressure affecting nsp12 (Tajima’s D = −2.62), with potential antiviral escape mutations in only 0.3% of sequenced genomes. Potential escape mutations included known key residues, such as Nsp12:Val473 and Nsp12:Arg555. Of the potential escape mutations involved globally, in silico structural models found that they were unlikely to be associated with loss of stability in RdRp. No potential escape mutation was found in a local cohort of remdesivir treated patients. Collectively, these findings indicate that RdRp is a suitable drug target, and that remdesivir does not seem to exert high selective pressure. We anticipate our framework to be the starting point of a larger effort for a global monitoring of drug resistance throughout the COVID-19 pandemic.

9 May 2023
Verified
Conference Paper
Open access
GPGianluca Palermo
Gianluca Palermo
GAG. Accordi
G. Accordi
DGDavide Gadioli
Davide Gadioli
EVE. Vitali
E. Vitali
CSC. Silvano
C. Silvano
PGP. Gschwandtner
P. Gschwandtner
Today digital revolution is having a dramatic impact on the pharmaceutical industry and the entire healthcare system. The implementation of machine learning, extreme-scale computer simulations, and big data analytics in the drug design and development process offers an excellent opportunity to lower the risk of investment and reduce the time to the patient. Within the LIGATE project 1, we aim to integrate, extend, and co-design best-in-class European components to design Computer-Aided Drug Design (CADD) solutions exploiting today's high-end supercomputers and tomorrow's Exascale resources, fostering European competitiveness in the field. The proposed LIGATE solution is a fully integrated workflow that enables to deliver the result of a virtual screening campaign for drug discovery with the highest speed along with the highest accuracy. The full automation of the solution and the possibility to run it on multiple supercomputing centers at once permit to run an extreme scale in silico drug discovery campaign in few days to respond promptly for example to a worldwide pandemic crisis.

4 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
Alfredo MariAlfredo Mari
Alfredo Mari
TRTim-Christoph Roloff
Tim-Christoph Roloff
MSMadlen Stange
Madlen Stange
KSKirstine K. Søgaard
Kirstine K. Søgaard
EAErblin Asllanaj
Erblin Asllanaj
AEAdrian Egli
Adrian Egli
Antiviral treatments for COVID-19 have involved many repurposed drugs. Currently, SARS-CoV-2 RNA-dependent RNA polymerase (RdRp, encoded by nsp12-nsp7-nsp8 ) has been targeted by numerous inhibitors with debated clinical impact. Among these, remdesivir has been conditionally approved for the treatment of COVID-19 patients. Although the emergence of antiviral resistance, an indirect proxy for antiviral efficacy, poses a considerable healthcare threat, an evolutionary perspective on emerging resistant mutants is still lacking. Here we show that SARS-CoV-2 RdRp is under purifying selection, that potential escape mutations are rare, and unlikely to lead to viral fitness loss. In more than 56,000 viral genomes from 105 countries dating from December 2019 to July 2020 we found negative selective pressure affecting nsp12 (Tajima’s D = −2.62), with potential antiviral escape mutations in only 0.3% of sequenced genomes. Those affected known key residues, such as Nsp12:Val473 and Nsp12:Arg555. Of the potential escape mutations found globally, in silico structural models show that this rarely implies loss of stability in RdRp. No potential escape mutation were found in our local cohort of remdesivir treated patients from the first wave (n=8). Our results indicate that RdRp is a suitable drug target, and that remdesivir does not seem to exert high selective pressure. Our study could be the starting point of a larger monitoring effort of drug resistance throughout the COVID-19 pandemic. We recommend the application of repetitive genome sequencing of SARS-CoV-2 from patients treated with antivirals to provide early insights into the evolution or antiviral resistance.

9 October 2025 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
LALeila T. Alexander
Leila T. Alexander
OFOcéane M. Follonier
Océane M. Follonier
AKAndriy Kryshtafovych
Andriy Kryshtafovych
KAKim Abesamis
Kim Abesamis
SBSabrina Bibi‐Triki
Sabrina Bibi‐Triki
TSTorsten Schwede
Torsten Schwede
This article presents an in‐depth analysis of selected CASP16 targets, with a focus on their biological and functional significance. The authors highlight the most relevant features of the target proteins and discuss how well these were reproduced in the submitted predictions. While the overall performance of structure prediction methods remains impressive, challenges persist, particularly in modeling rare structural motifs, flexible regions, small molecule interactions, posttranslational modifications, and biologically important interfaces. Addressing these limitations can strengthen the role of structure prediction in complementing experimental efforts and advancing both basic research and biomedical applications.